Lonza, a Swiss multinational, chemicals and biotechnology company, opened the world’s largest dedicated cell-and-gene-therapy facility, which was built in anticipation of the rising demand from developers of cell and gene therapies.
During a grand opening ceremony in Pearland, Texas (USA), Lonza executives and industry leaders will unveil the 27,870 square-meter facility and its offerings – highlighting its state-of-the-art, fully integrated, everything-under-one-roof access to some of the world’s most innovative cell-and-gene-therapy manufacturing technologies.
The Lonza Houston Center of Excellence is already operational and manufacturing for several customers. This facility is recruiting employees and will have more than 200 full-time staff including scientists, engineers and biotechnology professionals by the end of 2018 and continue to recruit high-value positions as market demand increases.
“Lonza Houston will serve as a center of excellence for cell-and-gene-therapy process development from concept through pre-clinical, clinical and commercialization, all the way to the patient,” says Andreas Weiler, Business Unit head for Emerging Technologies at Lonza Pharma & Biotech. “This facility has the potential to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases, under one roof. It will set a new standard in biopharmaceutical manufacturing and stand as one of four centers of excellence in cell and gene therapy in the only global network spanning three continents.”